New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 27, 2014
07:12 EDTMKGAYMerck KGaA CFO Matthias Zachert to step down
Matthias Zachert, Group CFO of Merck KGaA, Darmstadt, Germany, has informed the Chairman of the Family Board, Frank Stangenberg- Haverkamp, as well as the Chairman of the Merck KGaAExecutive Board, Karl-Ludwig Kley, that he has received the offer to be appointed as CEO of Lanxess AG, Cologne, Germany. He therefore asked for an early release of his duties. Merck will accept his request. The effective date will be announced in due course.
News For MKGAY From The Last 14 Days
Check below for free stories on MKGAY the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 18, 2014
06:21 EDTMKGAYMerck KGaA names Stefan Oschmann as deputy CEO
Subscribe for More Information
September 12, 2014
09:14 EDTMKGAYOn The Fly: Pre-market Movers
Subscribe for More Information
08:39 EDTMKGAYOncothyreon says Merck KGaA discontinues development of tecemotide in NSCLC
Oncothyreon (ONTY) disclosed earlier in a regulatory filing that Merck KGaA (MKGAY), which has world-wide rights for the development and commercialization of tecemotide under a license agreement with Oncothyreon, announced that its biopharmaceutical division will discontinue the clinical development program of the investigational MUC1 antigen-specific cancer immunotherapy as a monotherapy in Stage III non-small cell lung cancer, or NSCLC. The decision to discontinue the current clinical program in NSCLC, which includes the Phase III START2 and INSPIRE studies, follows recent results from a planned analysis of EMR 63325-009, a randomized, double-blind, placebo-controlled Phase I/II study in Japanese patients. Merck Serono has made the decision to discontinue all other Merck Serono-sponsored clinical trials with tecemotide in NSCLC worldwide. Those patients on active treatment with tecemotide can undergo an individual assessment by their treating physician and apply to receive further treatment outside of the studies. Merck Serono will continue to supply tecemotide for ongoing investigator-sponsored trials in other indications in accordance with their agreements with the sponsors of these studies. Shares of Oncothyreon are down 12% in pre-market trading following the news from its partner.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use